{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"To determine the MTD of pomalidomide administered orally in patients with Waldenstrom's Macroglobulinemia in combination with dexamethasone and rituximab. Because maximum tolerated dose was not determined due to study termination, the highest dose of pomalidomide administered is presented below.","groups":[{"description":"Drug: pomalidomide Taken orally once a day\n\nDrug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15\n\nDrug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15\n\npomalidomide: Taken orally once a day\n\ndexamethasone: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15\n\nrituximab: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15","id":"OG000","title":"Pomalidomide, Dexamethasone, Rituximab"}],"paramType":"NUMBER","populationDescription":"The maximum tolerated dose was not determined due to study termination. Three participants experienced IgM flare causing them to be removed from the study early.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Maximum Tolerated Dose of Pomalidomide","type":"PRIMARY","unitOfMeasure":"mg"}